Recognizing Lacosamide-Induced Arrhythmias
Lacosamide, an antiepileptic drug used for partial-onset seizures, can cause cardiac arrhythmias like bradycardia, atrioventricular (AV) block, atrial fibrillation, or ventricular tachycardia, especially in patients with underlying heart conditions or on interacting drugs. These effects stem from its sodium channel modulation, prolonging PR interval and risking conduction delays. Diagnosis involves ECG monitoring, correlating symptoms like dizziness or syncope with drug initiation or dose increases.
Primary Treatment: Drug Discontinuation
The first step is immediate discontinuation or dose reduction of lacosamide under medical supervision. Symptoms often resolve within days as the drug's half-life is 13 hours, with full clearance in 2-3 days. In a 2018 case series, 85% of patients with PR prolongation normalized after withdrawal.[1] Hospitalization with telemetry monitoring is standard for severe cases.
Supportive Cardiac Interventions
- For bradycardia or AV block: Atropine (0.5-1 mg IV) provides temporary relief; temporary pacing if hemodynamically unstable.
- For ventricular arrhythmias: Lidocaine or amiodarone infusion; defibrillation for sustained VT/VF.
- General stabilization: IV fluids, electrolytes (correct hypokalemia/magnesemia), and oxygen. Avoid beta-blockers, which worsen conduction issues.
In overdose scenarios, lipid emulsion therapy (Intralipid 20%, 1.5 mL/kg bolus) has stabilized patients by binding lacosamide, per toxicology reports.[2]
Managing Underlying Seizures During Switch
Abrupt stop risks status epilepticus, so transition to alternatives like levetiracetam, valproate, or lamotrigine. Benzodiazepines (lorazepam 0.1 mg/kg IV) bridge acute seizures. A 2020 review recommends cardiology consult and Holter monitoring pre-rechallenge.[3]
When Can Lacosamide Be Retried?
Reintroduction at lower doses (e.g., 100-200 mg/day) succeeds in 30-50% of select patients without cardiac history, with serial ECGs. Contraindicated in 2nd/3rd-degree AV block or sick sinus syndrome.
Risk Factors and Prevention Strategies
Higher risk in elderly, renal/hepatic impairment, or with drugs like beta-blockers/carbamazepine. Baseline ECG and monitoring every 3-6 months advised. Genetic factors like SCN5A variants may predispose.
Long-Term Monitoring and Alternatives
Post-event, implantable loop recorders track recurrence. Switch permanently to non-sodium channel agents:
| Alternative | Key Advantages | Common Doses |
|-------------|----------------|--------------|
| Levetiracetam | No cardiac effects | 1000-3000 mg/day |
| Brivaracetam | Faster onset, cardiac-safe | 50-200 mg/day |
| Topiramate | Broad efficacy | 100-400 mg/day |
Consult epileptologist and cardiologist; pacemaker implantation rare but considered for recurrent blocks.
[1] Lacosamide-associated cardiac conduction abnormalities
[2] Lacosamide overdose management
[3] Cardiac safety of lacosamide review